Gilead loses bid to quash parallel antitrust HIV lawsuit

Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Big pharma firm settles HIV drug disputes with generic makers

13 September 2022 Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Generics

Aetna gets antitrust suit moved back to state court

25 April 2022 American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

More on this story

Americas

Big pharma firm settles HIV drug disputes with generic makers

13 September 2022 Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Generics

Aetna gets antitrust suit moved back to state court

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

More on this story

Americas

Big pharma firm settles HIV drug disputes with generic makers

13 September 2022 Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Generics

Aetna gets antitrust suit moved back to state court

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS